The Allowed Claims include Composition of FT-104 and Provides Protection until 2040 TORONTO, April 05, 2022 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, today announced that the U.S. Patent and Trademark Office (“USPTO”) has granted the Company a patent for claims related to FT-104…


Previous articlePT307 – Kathryn L. Tucker, JD – The Right to Try Act and the Battle for Psilocybin Access
Next articlePsychedelic Bulletin: Homecoming Raises $4m Seed; Angermayer Increases atai Stake by 1m Shares; 6 Projects Readers are Working On